Article Text

The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis
  1. Martin Duddy1,
  2. Jacqueline Palace2
  1. 1Department of Neurology, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne, UK
  2. 2Department of Clinical Neurology, Oxford University Hospitals Trust, Oxford, UK
  1. Correspondence to Dr Martin Duddy, Department of Neurology, Newcastle upon Tyne Hospitals Trust, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; martin.duddy{at}

Statistics from

The UK's National Institute for Health and Care Excellence (NICE)1 technology appraisal of disease-modifying therapies for multiple sclerosis stated, “on the balance of their clinical and cost effectiveness, neither beta interferon nor glatiramer acetate is recommended for the treatment of multiple sclerosis in the National Health Service (NHS) in England and Wales”. However, recognising that the drugs might prove cost-effective if assessed over longer than the phase 3 trials, which are conducted for 2–3 years, NICE invited the relevant authorities to consider a strategy to deliver the drugs within a £36 000/quality-adjusted life years (QALY) target, modelled over 20 years. Thus the UK risk-sharing scheme was born, tracking the progress over 10 years of a cohort of patients who started disease-modifying treatments between 2002 and 2005.2

The 6-year analysis has just been published.3 Two different models were used to predict the course of the untreated cohort: a continuous Markov model (PAREXEL)4 and a multilevel model (University of Bristol, UK).5i Both used data from historical, untreated patients in the British Columbia multiple sclerosis database, who would have qualified for treatment if available. A value for utility (quality of life compared with full health) was assigned to each Expanded Disability Status Scale (EDSS) grade. Having modelled the decline in utility expected, it was calculated that a cost-effective treatment would need to reduce this by 38%.

The primary analysis of the scheme shows that, on aggregate, the drugs perform beyond target at 6 years, with both models showing a 42% reduction in the predicted progression of utility. This primary analysis is restricted to the cohort of 4137 (of 5610) who had …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.